Cargando…

Editorial: Microbiome in IBD: From Composition to Therapy

Detalles Bibliográficos
Autores principales:	Zhu, Ruixin, He, Peijian, Liu, Zhanju, Liu, Ningning, Miao, Yinglei, Yu, Chenggong, Zhu, Lixin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8263897/ https://www.ncbi.nlm.nih.gov/pubmed/34248651 http://dx.doi.org/10.3389/fphar.2021.721992

Ejemplares similares

Editorial: Microbiome in IBD: From Composition to Therapy, Volume II
por: Liu, Ning-Ning, et al.
Publicado: (2023)

Editorial: IBD Management—Novel Targets and Therapeutic Perspectives
por: Antonioli, Luca, et al.
Publicado: (2020)

IBD Subtype-Regulators IFNG and GBP5 Identified by Causal Inference Drive More Intense Innate Immunity and Inflammatory Responses in CD Than Those in UC
por: Gao, Sheng, et al.
Publicado: (2022)

Drugs and Targets in Fibrosis
por: Li, Xiaoyi, et al.
Publicado: (2017)

Role of Pyroptosis in Inflammatory Bowel Disease (IBD): From Gasdermins to DAMPs
por: Zhang, Shuxia, et al.
Publicado: (2022)

TOB1 Blocks Intestinal Mucosal Inflammation Through Inducing ID2-Mediated Suppression of Th1/Th17 Cell Immune Responses in IBD
por: Lin, Ritian, et al.
Publicado: (2021)

Oligonucleotides—A Novel Promising Therapeutic Option for IBD
por: Scarozza, Patrizio, et al.
Publicado: (2019)

Editorial: Nonalcoholic fatty liver disease therapy: Exploring molecular mechanisms of well-defined composition from natural plants
por: Zhang, Wenji, et al.
Publicado: (2022)

Targeting the Eph/Ephrin System as Anti-Inflammatory Strategy in IBD
por: Grandi, Andrea, et al.
Publicado: (2019)

Claudins: Beyond Tight Junctions in Human IBD and Murine Models
por: Čužić, Snježana, et al.
Publicado: (2021)

The gut microbiota heterogeneity and assembly changes associated with the IBD
por: Sun, Yang, et al.
Publicado: (2019)

Hsp60 as a Novel Target in IBD Management: A Prospect
por: Cappello, Francesco, et al.
Publicado: (2019)

Editorial: Epigenetic regulation and therapy resistance in cancer
por: Zhu, Yongxia, et al.
Publicado: (2023)

Integrating the serum proteomic and fecal metaproteomic to analyze the impacts of overweight/obesity on IBD: a pilot investigation
por: Yan, Ping, et al.
Publicado: (2023)

Effects of Pranoprofen on Aqueous Humor Monocyte Chemoattractant Protein-1 Level and Pain Relief During Second-Eye Cataract Surgery
por: Zhang, Yinglei, et al.
Publicado: (2018)

Intercontinental Gut Microbiome Variances in IBD
por: Mayorga, Luis, et al.
Publicado: (2022)

Editorial: Ulcerative colitis disease therapy: Unveiling the molecular mechanisms of well-defined composition from natural plants
por: Tao, Yi, et al.
Publicado: (2023)

Multipronged Therapeutic Effects of Chinese Herbal Medicine Qishenyiqi in the Treatment of Acute Myocardial Infarction
por: Wang, Yong, et al.
Publicado: (2017)

Advances of Heat Shock Family in Ulcerative Colitis
por: Gong, Min, et al.
Publicado: (2022)

Editorial: Clinical Therapeutic Development Against Cancers Resistant to Targeted Therapies
por: Zhou, Fanfan, et al.
Publicado: (2022)

Probiotic Lactobacilli Isolated from Kefir Promote Down-Regulation of Inflammatory Lamina Propria T Cells from Patients with Active IBD
por: Curciarello, Renata, et al.
Publicado: (2021)

The Interplay Between Use of Biological Therapies, Psychological State, and the Microbiome in IBD
por: Tavakoli, Paris, et al.
Publicado: (2022)

Editorial: Fibrosis: etiology, pathophysiology, measurements, and therapy
por: Liu, Yanping, et al.
Publicado: (2023)

Editorial: Adaptive immune resistance in cancer therapy
por: Jiang, Aimin, et al.
Publicado: (2023)

Editorial: Chemical composition and antimicrobial activity of essential oils
por: Božović, Mijat, et al.
Publicado: (2023)

Editorial: Mitochondrial therapy in neurodegeneration
por: Kalani, Anuradha, et al.
Publicado: (2023)

LightCUD: a program for diagnosing IBD based on human gut microbiome data
por: Xu, Congmin, et al.
Publicado: (2021)

Editorial: Advances in drug-induced diseases
por: Liu, Yao, et al.
Publicado: (2023)

Editorial: Advancing Genomics for Rare Disease Diagnosis and Therapy Development
por: Liu, Zhichao, et al.
Publicado: (2020)

Editorial: Current trends and future management of IBD
por: Estevinho, María Manuela, et al.
Publicado: (2023)

Bifidobacterium longum CECT 7894 Improves the Efficacy of Infliximab for DSS-Induced Colitis via Regulating the Gut Microbiota and Bile Acid Metabolism
por: Xiao, Fangfei, et al.
Publicado: (2022)

Explore the Anti-Acne Mechanism of Licorice Flavonoids Based on Metabonomics and Microbiome
por: Ruan, Shi-Fa, et al.
Publicado: (2022)

Modulation of cytokine patterns and microbiome during pregnancy in IBD
por: van der Giessen, Janine, et al.
Publicado: (2020)

Editorial: New Therapies in the Field of Rheumatology
por: Chighizola, Cecilia Beatrice, et al.
Publicado: (2020)

Editorial: Novel biomarkers for anticancer therapy
por: Wang, Ting, et al.
Publicado: (2023)

Microbiome-Metabolomics Analysis Reveals the Protection Mechanism of α-Ketoacid on Adenine-Induced Chronic Kidney Disease in Rats
por: Mo, Yenan, et al.
Publicado: (2021)

Editorial: Functional Nanomaterials in Inflammatory Diseases: From Prevention to Diagnosis and Therapy
por: Evans, Colin E., et al.
Publicado: (2021)

Microbial genes outperform species and SNVs as diagnostic markers for Crohn’s disease on multicohort fecal metagenomes empowered by artificial intelligence
por: Gao, Sheng, et al.
Publicado: (2023)

Targeting Anion Exchange of Osteoclast, a New Strategy for Preventing Wear Particles Induced- Osteolysis
por: Wu, Chuanlong, et al.
Publicado: (2018)

Corrigendum: Targeting Anion Exchange of Osteoclast, a New Strategy for Preventing Wear Particles Induced-Osteolysis
por: Wu, Chuanlong, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_ascklj9pc95i3833sj617jut95